QuidelOrtho Corp (QDEL): Cash & Equivalents
$169.80M
As of 2025-12-28
$123.40M
As of 2026-06-28
-16.6%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $169.80M | +72.7% | 2026-02-19, Balance as of period end |
| 2024-12-29 | $98.30M | -17.3% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $118.90M | -59.4% | 2025-02-27, Balance as of period end |
| 2023-01-01, Fiscal 2022 | $292.90M | -63.5% | 2024-08-01, Balance as of period end |
| 2022-01-02, Fiscal 2021 | $802.80M | n/a | 2023-02-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $169.80M | +72.7% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $180.07M | -37.5% |
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $359.12M | -60.7% |
| Neogen Corp (NEOG) | 2026-05-31 | $185.50M | +43.8% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $149.60M | +46.1% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $155.46M | -17.8% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $5.91M | +59.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.81M | +1.3% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $1.75M | -0.8% |
Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗